2017
DOI: 10.5603/kp.a2017.0141
|View full text |Cite
|
Sign up to set email alerts
|

Viral heart disease — treatment

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 30 publications
0
2
0
Order By: Relevance
“…This suggests that the virus spectrum of myocarditis may ; Table 5). b Expanded access in cases of B19V-associated cardiomyopathy with high replication and clinical impairment (New York Heart Association III and/or LVEF < 30%), individualized decision based on expert opinion and scientific proceedings publications; 45,46 600 mg telbivudine was given p.o. for 6 months.…”
Section: Discussionmentioning
confidence: 99%
“…This suggests that the virus spectrum of myocarditis may ; Table 5). b Expanded access in cases of B19V-associated cardiomyopathy with high replication and clinical impairment (New York Heart Association III and/or LVEF < 30%), individualized decision based on expert opinion and scientific proceedings publications; 45,46 600 mg telbivudine was given p.o. for 6 months.…”
Section: Discussionmentioning
confidence: 99%
“…The acute phase may also lead to death or severe dilated cardiomyopathy in 12% to 25% of cases. 84 The immune mechanism is the key contributor to myocardial damage due to myocarditis. The NK cells, which exert cardioprotective effect by inhibiting virus replication, are the first to reach the infected myocardium.…”
Section: Risk Factorsmentioning
confidence: 99%